Valneva reports positive pivotal phase 3 immunogenicity data in adolescents for its single-shot chikungunya vaccine candidate

Saint-herblain (france), november 13, 2023 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported positive pivotal phase 3 immunogenicity data in adolescents for its single-dose chikungunya virus (chikv) vaccine candidate vla1553. these results complement the initial phase 3 safety data the company reported for the trial in august 20231.
VALN Ratings Summary
VALN Quant Ranking